Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 7Breast Neoplasms 3Zollinger-Ellison Syndrome 1Triple Negative Breast Neoplasms 1Stomach Ulcer 1Solid Tumours 1Solid Tumor 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Ovarian Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Healthy Adult Participants 1Esophagitis, Peptic 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms, Male 1Advanced Solid Tumours 1Advanced Solid Tumors 1Advanced Solid Tumor 1Adult Solid Neoplasm 1

Interventions

repaglinide 1Warfarin 1Omeprazole 1Midazolam 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Prostate Cancer Patients × Omeprazole × Clear all
NCT04676035 2023-02-09

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡